



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/44, C07D 213/72	A1	(11) International Publication Number: WO 97/30708 (43) International Publication Date: 28 August 1997 (28.08.97)
(21) International Application Number: PCT/US97/02408 (22) International Filing Date: 18 February 1997 (18.02.97) (30) Priority Data: 60/012,058 22 February 1996 (22.02.96) US 9605643.7 18 March 1996 (18.03.96) GB (71) Applicant (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): SANDERSON, Philip, E. [GB/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). LYLE, Terry, A. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). VACCA, Joseph, P. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). LUMMA, William, C. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). BRADY, Stephen, F. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). TUCKER, Thomas, J. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (74) Common Representative: MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).	(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report.	

(54) Title: PYRIDINONE THROMBIN INHIBITORS



(57) Abstract

Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions and have structure (I), for example (II).

Ref. #10
3202/2 (PHA4160.3)
M. South et al.
09/716,962

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

- 1 -

TITLE OF THE INVENTION**PYRIDINONE THROMBIN INHIBITORS****BACKGROUND OF THE INVENTION**

5 Thrombin is a serine protease present in blood plasma in the form of a precursor, prothrombin. Thrombin plays a central role in the mechanism of blood coagulation by converting the solution plasma protein, fibrinogen, into insoluble fibrin.

 Edwards *et al.*, *J. Amer. Chem. Soc.*, (1992) vol. 114, pp.
10 1854-63, describes peptidyl α -ketobenzoxazoles which are reversible inhibitors of the serine proteases human leukocyte elastase and porcine pancreatic elastase.

 European Publication 363 284 describes analogs of peptidase substrates in which the nitrogen atom of the scissile amide
15 group of the substrate peptide has been replaced by hydrogen or a substituted carbonyl moiety.

 Australian Publication 86245677 also describes peptidase inhibitors having an activated electrophilic ketone moiety such as fluoromethylene ketone or α -keto carboxyl derivatives.

20 R. J. Brown *et al.*, *J. Med. Chem.*, Vol. 37, pages 1259-1261 (1994) describes orally active, non-peptidic inhibitors of human leukocyte elastase which contain trifluoromethylketone and pyridinone moieties.

 H. Mack *et al.*, *J. Enzyme Inhibition*, Vol. 9, pages 73-86
25 (1995) describes rigid amidino-phenylalanine thrombin inhibitors which contain a pyridinone moiety as a central core structure.

SUMMARY OF THE INVENTION

30 The invention includes a composition for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier. These compositions may optionally include anticoagulants, antiplatelet agents,

- 2 -

and thrombolytic agents. The compositions can be added to blood, blood products, or mammalian organs in order to effect the desired inhibitions.

The invention also includes a composition for preventing or treating unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels, in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier. These compositions may optionally include anticoagulants, antiplatelet agents, and thrombolytic agents.

The invention also includes a method for reducing the thrombogenicity of a surface in a mammal by attaching to the surface, either covalently or noncovalently, a compound of the invention.

The invention also includes the use of a compound of the invention, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for inhibiting thrombus formation, preventing thrombus formation, inhibiting thrombin, inhibiting formation of fibrin, and inhibiting formation of blood platelet aggregates, in a mammal

Some abbreviations that may appear in this application are as follows.

ABBREVIATIONS

Designation

BOC (Boc)

CBZ (Cbz)

TBS (TBDMS)

Protecting Group

t-butyloxycarbonyl

benzyloxycarbonyl(carbobenzoxy)

t-butyl-dimethylsilyl

Activating Group

HBT(HOBT or HOBT) 1-hydroxybenzotriazole hydrate


- 3 -

<u>Designation</u>	<u>Coupling Reagent</u>
BOP reagent	benzotriazol-1-yloxytris-(dimethylamino)phosphonium hexafluorophosphate
BOP-Cl	bis(2-oxo-3-oxazolidinyl)phosphinic chloride
EDC	1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride
	<u>Other</u>
(BOC) ₂ O (BOC ₂ O)	di-t-butyl dicarbonate
n-Bu ₄ N ⁺ F ⁻	tetrabutyl ammonium fluoride
nBuLi (n-Buli)	n-butyllithium
DMF	dimethylformamide
Et ₃ N (TEA)	triethylamine
EtOAc	ethyl acetate
TFA	trifluoroacetic acid
DMAP	dimethylaminopyridine
DME	dimethoxyethane
NMM	N-methylmorpholine
DPPA	diphenylphosphoryl azide
THF	tetrahydrofuran
DIPEA	diisopropylamine
	<u>Amino Acid</u>
Ile	Isoleucine
Phe	Phenylalanine
Pro	Proline
Ala	Alanine
Val	Valine

- 4 -

DETAILED DESCRIPTION OF THE INVENTION AND PREFERRED EMBODIMENTS

Compounds of the invention are useful as thrombin inhibitors and have therapeutic value in for example, preventing coronary artery disease, and have the following structure:



wherein

W is

- 10 hydrogen,
- R¹-,
- R¹OC(O)-,
- R¹C(O)-,
- R¹SO₂-,
- 15 R¹NHSO₂-,
- (R¹)₂NSO₂-,
- R¹(CH₂)_nNHC(O)-,
- (R¹)₂CH(CH₂)_nNHC(O)-, or
- wherein n is 0-4;

20

R¹ is

- R²(CH₂)_r, where r is 0-4,
- (R²)(OR²)CH(CH₂)_p-, where p is 1-4,
- (R²)₂CH(CH₂)_r-, where r is 0-4 and each R² can be the same or
- 25 different, and wherein (R²)₂ can also form a ring with CH
- represented by C₃-7 cycloalkyl, C₇-12 bicyclic alkyl, C₁₀-16
- tricyclic alkyl, or a 5- to 7- membered mono- or bicyclic

- 5 -

heterocyclic ring which can be saturated or unsaturated, and
which contains from one to three heteroatoms selected from the
group consisting of N, O and S,
R²O(CH₂)_p-, wherein p is 1-4, or
5 R²(COOR³)(CH₂)_r-, where r is 1-4;

R² and R¹⁴ are independently selected from
-phenyl, unsubstituted or substituted with one or more of
C₁₋₄ alkyl, C₁₋₄ alkoxy, halogen, hydroxy, COOH, or CONH₂,
10 naphthyl,
biphenyl,
a 5- to 7- membered mono- or a 9- to 10-membered bicyclic
heterocyclic ring which can be saturated or unsaturated, and
which contains from one to four heteroatoms selected from the
15 group consisting of N, O and S,
C₁₋₄ alkyl,
C₃₋₇ cycloalkyl,
C₇₋₁₂ bicyclic alkyl, or
C₁₀₋₁₆ tricyclic alkyl;

20 R³ and R^{3'} are independently
C₁₋₄ alkyl,
C₃₋₇ cycloalkyl, or
trifluoromethyl;

25 R⁴ is
hydrogen,
C₁₋₄ alkyl,
C₁₋₄ alkoxy,
30 halogen,
-OCH₂CF₃,
-COOH,
-OH,
-COOR⁶, where R⁶ is C₁₋₄alkyl,

- 6 -

- CONR⁷R⁸, where R⁷ and R⁸ are independently hydrogen or C₁₋₄alkyl,
- 5 -(CH₂)₁₋₄OH,
 -CH₂NHC(O)CH₃,
 -CH₂NHC(O)CF₃,
 -CH₂NHSO₂CH₃,
 -SO₂NH₂,
 -(CH₂)₁₋₄SO₂NR⁷R⁸,
 -(CH₂)₁₋₄SO₂R⁶,
- 10 a 5- to 7- membered mono- or a 9- to 10-membered bicyclic heterocyclic ring which can be saturated or unsaturated, and which contains from one to four heteroatoms selected from the group consisting of N, O and S,
- 15 -XCH₂CO₂H,
 -XCH₂CO₂CH₃,
 -XCH₂CO₂(CH₂)₁₋₃CH₃,
 -X(CHR⁹)₁₋₃C(O)NR¹⁰R¹¹,
- 20 wherein
 R⁹ is H or C₁₋₄ alkyl,
 R¹⁰ and R¹¹ are independently
 hydrogen,
 C₃₋₇ cycloalkyl,
 aryl,
 heteroaryl,
- 25 heterocycloalkyl,
 C₁₋₄ alkyl unsubstituted or substituted with one or more of
 hydroxy,
 COOH,
 amino,
30 dialkylamino,
 aryl,
 heteroaryl, or
 heterocycloalkyl, or
 R¹⁰ and R¹¹ are joined to form a four to seven

- 7 -

membered cycloalkyl ring unsubstituted or substituted with hydroxy, amino or aryl, or -XCH₂R¹⁴,

5 wherein X is O, S or CH₂;

R⁵ is

hydrogen,
halogen,
10 C₁₋₄ alkyl,
 C₁₋₄ alkoxy,
 CN, or
 CO₂NH₂,

and pharmaceutically acceptable salts thereof.

15 In one class of compounds and pharmaceutically acceptable salts thereof, W is R¹ or R¹SO₂.

In a subclass of this class of compounds and pharmaceutically acceptable salts thereof, R¹ is R²(CH₂)_r, or (R²)₂CH(CH₂)_r, phenyl-CH₂SO₂, or diphenyl-CHSO₂.

20 In a group of this subclass of compounds and pharmaceutically acceptable salts thereof, R¹ is phenyl-CH₂SO₂, or diphenyl-CHSO₂.

In a subgroup of this group of compounds and pharmaceutically acceptable salts thereof, R³ is C₁₋₄ alkyl.

25 In a family of this subgroup of compounds and pharmaceutically acceptable salts thereof, R³ is methyl and R^{3'} is hydrogen.

In a subfamily of this family of compounds and pharmaceutically acceptable salts thereof,

30 R⁴ is

hydrogen,
chlorine,
OH,

- 8 -




OCH₂CF₃
OCH₂C(O)NH₂
OCH₂C(O)NHCH₂CH₃, or
OCH₂C(O)NH(CH₂CH₂CH₃); and

5

R⁵ is chlorine.




Specific embodiments of this subfamily include (note that the methyl group is conventionally indicated as a single bond attached to a ring):

10




15

- 9 -



5



10 The compounds of the present invention, may have chiral centers and occur as racemates, racemic mixtures and as individual diastereomers, or enantiomers with all isomeric forms being included in the present invention. A racemate or racemic mixture does not imply a 50:50 mixture of stereoisomers.

- 10 -

When any variable occurs more than one time in any constituent or in formula I, its definition on each occurrence is independent of its definition at every other occurrence. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.

As used herein except where noted, "alkyl" is intended to include both branched- and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms (Me is methyl, Et is ethyl, Pr is propyl, Bu is butyl); "alkoxy" represents a linear or branched alkyl group of indicated number of carbon atoms attached through an oxygen bridge; "Halo", as used herein, means fluoro, chloro, bromo and iodo; and "counterion" is used to represent a small, single negatively-charged species, such as chloride, bromide, hydroxide, acetate, trifluoroacetate, perchlorate, nitrate, benzoate, maleate, sulfate, tartrate, hemitartrate, benzene sulfonate, and the like.

The term "C₃₋₇cycloalkyl" is intended to include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl, and the like.

The term "C₇₋₁₂ bicyclic alkyl" is intended to include bicyclo[2.2.1]heptyl (norbornyl), bicyclo[2.2.2]octyl, 1,1,3-trimethylbicyclo[2.2.1]heptyl (bornyl), and the like.

The term aryl as used herein except where noted, represents a stable 6- to 10-membered mono- or bicyclic ring system such as phenyl, or naphthyl. The aryl ring can be unsubstituted or substituted with one or more of C₁₋₄ lower alkyl; hydroxy; alkoxy; halogen; amino.

The term "heterocycle" or "heterocyclic ring", as used herein except where noted, represents a stable 5- to 7-membered mono- or bicyclic or stable 7- to 10-membered bicyclic heterocyclic ring system any ring of which may be saturated or unsaturated, and which consists of carbon atoms and from one to four heteroatoms selected from the group consisting of N, O and S, and wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring.

- 11 -

Especially useful are rings containing one oxygen or sulfur, one to four nitrogen atoms, or one oxygen or sulfur combined with one or two nitrogen atoms. The heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure.

- 5 Examples of such heterocyclic groups include piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolodinyl, 2-oxoazepinyl, azepinyl, pyrrolyl, 4-piperidonyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl, imidazolyl, imidazoliny, imidazolidinyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidinyl,
- 10 morpholinyl, thiazolyl, thiazolidinyl, isothiazolyl, quinuclidinyl, isothiazolidinyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl, thiadiazoyl, benzopyranyl, benzothiazolyl, benzoxazolyl, furyl, tetrahydrofuryl, tetrahydropyranyl, tetrazole, thienyl, benzothienyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, and
- 15 oxadiazolyl. Morpholino is the same as morpholinyl.

The pharmaceutically-acceptable salts of the compounds of Formula I (in the form of water- or oil-soluble or dispersible products) include the conventional non-toxic salts or the quaternary ammonium salts which are formed, e.g., from inorganic or organic acids or bases.

- 20 Examples of such acid addition salts include acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride,
- 25 hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, sulfate, tartrate, thiocyanate, tosylate, and undecanoate. Base salts include ammonium salts, alkali metal salts such
- 30 as sodium and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, and so forth. Also, the basic nitrogen-containing groups may be quaternized with such agents as lower alkyl halides, such as

- 12 -

methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl; and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides and others.

5

Thrombin Inhibitors - Therapeutic Uses- Method of Using

Anticoagulant therapy is indicated for the treatment and prevention of a variety of thrombotic conditions, particularly coronary artery and cerebrovascular disease. Those experienced in this field are readily aware of the circumstances requiring anticoagulant therapy. The term "patient" used herein is taken to mean mammals such as primates, including humans, sheep, horses, cattle, pigs, dogs, cats, rats, and mice.

Thrombin inhibition is useful not only in the anticoagulant therapy of individuals having thrombotic conditions, but is useful whenever inhibition of blood coagulation is required such as to prevent coagulation of stored whole blood and to prevent coagulation in other biological samples for testing or storage. Thus, the thrombin inhibitors can be added to or contacted with any medium containing or suspected of containing thrombin and in which it is desired that blood coagulation be inhibited, e.g. when contacting the mammal's blood with material selected from the group consisting of vascular grafts, stents, orthopedic prosthesis, cardiac prosthesis, and extracorporeal circulation systems

The thrombin inhibitors of the invention can be administered in such oral forms as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixers, tinctures, suspensions, syrups, and emulsions. Likewise, they may be administered in intravenous (bolus or infusion), intraperitoneal, subcutaneous, or intramuscular form, all using forms well known to those of ordinary skill in the pharmaceutical arts. An effective but non-toxic amount of the compound desired can be employed as an anti-aggregation agent. For treating ocular build up of fibrin, the compounds may be administered intraocularly or topically as well as orally or parenterally.

The thrombin inhibitors can be administered in the form of a depot injection or implant preparation which may be formulated in such a

- 13 -

manner as to permit a sustained release of the active ingredient. The active ingredient can be compressed into pellets or small cylinders and implanted subcutaneously or intramuscularly as depot injections or implants. Implants may employ inert materials such as biodegradable
5 polymers or synthetic silicones, for example, Silastic, silicone rubber or other polymers manufactured by the Dow-Corning Corporation.

The thrombin inhibitors can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be
10 formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.

The thrombin inhibitors may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled. The thrombin inhibitors may also be coupled
15 with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxy-propyl-methacrylamide-phenol, polyhydroxyethyl-aspartamide-phenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues. Furthermore, the thrombin inhibitors may be coupled to a class of
20 biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic acid and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross linked or amphipathic block copolymers of hydrogels.

25 The dosage regimen utilizing the thrombin inhibitors is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound or salt thereof
30 employed. An ordinarily skilled physician or veterinarian can readily determine and prescribe the effective amount of the drug required to prevent, counter, or arrest the progress of the condition.

Oral dosages of the thrombin inhibitors, when used for the indicated effects, will range between about 0.1 mg per kg of body weight

- 14 -

per day (mg/kg/day) to about 100 mg/kg/day and preferably 1.0-100 mg/kg/day and most preferably 1-20 mg/kg/day. A suitably prepared medicament for once a day administration would thus contain between 9 mg and 9 g, preferably between 90 mg and 9 g, and most preferably
5 between 90 mg and 1.8 g, e.g. 100mg, 500 mg and 1 g. Advantageously, the thrombin inhibitors may be administered in divided doses of two, three, or four times daily. For such multiple administration, individual medicament strengths can be, for example, 25 mg, 33 mg or 50 mg. .
10 Intravenously, the most preferred doses will range from about 0.01 to about 10 mg/kg/minute during a constant rate infusion. Furthermore, they can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in that art. To be administered in the form of a transdermal delivery system, the
15 dosage administration will, or course, be continuous rather than intermittent throughout the dosage regime.

The thrombin inhibitors are typically administered as active ingredients in admixture with suitable pharmaceutical diluents, excipients or carriers (collectively referred to herein as "carrier"
20 materials) suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixers, syrups and the like, and consistent with convention pharmaceutical practices.

For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-
25 toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like; for oral administration in liquid form, the oral drug components can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as
30 ethanol, glycerol, water and the like. Moreover, when desired or necessary, suitable binders, lubricants, distintegrating agents and coloring agents can also be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn-sweeteners, natural and synthetic gums such as acacia, tragacanth or

- 15 -

sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. Disintegrators include, without limitation, starch methyl cellulose, agar, bentonite, xanthan gum and the like.

The thrombin inhibitors can also be co-administered with suitable anti-coagulation agents, including, but not limited to, fibrinogen receptor antagonists, heparin, aspirin, or warfarin, or thrombolytic agents such as plasminogen activators or streptokinase to achieve synergistic effects in the treatment of various ascular pathologies. For example, thrombin inhibitors enhance the efficiency of tissue plasminogen activator-mediated thrombolytic reperfusion. Thrombin inhibitors may be administered first following thrombus formation, and tissue plasminogen activator or other plasminogen activator is administered thereafter.


METHODS OF MAKING

The following synthetic methods can be used to prepare the compounds of the present invention:

As exemplified by Example 1 (Scheme 1).

Starting 6-methyl-2-hydroxy-pyridine-3-carboxylic acid is reacted with diphenylphosphoryl azide (DPPA) and benzyl alcohol in Step A to afford the protected aminopyridine. This is alkylated in Step B with t-butylbromoacetate and the CBZ group is removed in Step C by hydrogenation over a catalyst. The resulting amine is then reacted with the appropriate reagent, in this case benzylsulfonyl chloride, in Step D with pyridine as an acid scavenger and the t-butyl ester is then removed under acidic conditions in Step E. The acid is then coupled in Step F with an amine, such as 2,5-dichlorobenzylamine, to afford the final product.

- 16 -

SCHEME 1

- Amide couplings, e.g., Step F in Scheme 1, to form the
- 5 compounds of this invention can be performed by the carbodiimide method with reagents such as dicyclohexylcarbodiimide, or 1-ethyl-3-(3-dimethyl-aminopropyl) carbodiimide. Other methods of forming the amide or peptide bond include, but are not limited to the synthetic routes via an acid chloride, azide, mixed anhydride or activated ester.

- 17 -


Typically, solution phase amide couplings are performed, but solid-phase synthesis by classical Merrifield techniques may be employed instead. The addition and removal of one or more protecting groups is also typical practice.

- 5 Modifications of the method will allow different W, R³, R⁴ and R⁵ groups contemplated by the scope of the broad claim below to be present by the use of an appropriate reagent or appropriately substituted starting material in the indicated synthetic step. For example the starting pyridine in Step A, can have as the 6-substituent, ethyl, isopropyl, 10 cyclopropyl, trifluoromethyl, and the like, to achieve the different operable values of R³. Likewise, different W groups can be present by the use of an appropriate alkylating, carbonylating, sulfonylating, urealating agent, and the like, in Step D. Use of, for example, an alkyl halide, alkoxycarbonyl halide, acyl halide, alkylsulfonyl halide, or alkyl 15 isocyanate will yield the corresponding values of W where W is R¹, R¹OCO, R¹CO, R¹SO₂, or (R¹)_m(CH₂)_nNCO. Likewise, an appropriate choice of the amine in Step F will allow the different operable values of R⁴ and R⁵ to be achieved. Obvious variations and modifications of the method to produce similar and obvious variants 20 thereof, will be apparent to one skilled in the art.

A method for preparing compounds which contain, or are derivatives of, 2-hydroxybenzylamine as an end group is illustrated in Scheme 2 and is exemplified by Example 2.

- 25 4-Chlorosalicaldehyde is condensed with hydroxylamine hydrochloride in ethanolic aqueous sodium carbonate solution. The oxime is reduced by hydrogenation over a catalyst such as rhodium and the amine is protected as its BOC derivative under standard conditions. The phenol is alkylated in Step D with an acetate equivalent such as ethylbromoacetate and the resulting ester is hydrolysed with lithium 30 hydroxide. The product carboxylic acid is coupled to an amine such as ethylamine in Step F, and the BOC group is removed by strong acid. The amine is coupled to the product of Scheme 1, Step E to give the final product.

- 18 -

SCHEME 2

- 19 -


Modifications of this method will allow different R^4 and R^5 groups contemplated by the scope of the broad claim below to be present by the use of an appropriate reagent or appropriately substituted starting material in the indicated synthetic step. For example, appropriate choice of the amine in Step F will allow different values of R^7 and R^8 to be achieved. Obvious variations and modifications of the method to produce similar and obvious variants thereof, will be apparent to one skilled in the art.

A method for preparing compounds which are derivatives of 3-amino-4-trifluoromethyl-2-pyridinone is illustrated in Scheme 3. In Step A, 1,1,1, trifluoro-2,4-pentanedione is condensed with nitroacetamide in ethanolic diethylamine to give 2-hydroxy-6-methyl-3-nitro-4-trifluoromethylpyridine. This is alkylated in Step B with an acetate equivalent such as t-butyl bromoacetate in THF using sodium hydride as a base and the nitro group is reduced in Step C by hydrogenation using a catalyst such as palladium on carbon. The t-butyl group is removed in Step D by a strong acid such as HCl and the resulting carboxylic acid is coupled to ethyl-2-aminomethyl-4-chlorophenoxyacetamide in Step E to give the final product.

Modifications of the method will allow different R^3 , R^4 and R^5 groups contemplated by the scope of the broad claim below to be present by the use of an appropriate reagent or appropriately substituted starting material in the indicated synthetic step. For example use of the appropriate dione in Step A will allow the different operable values of R^3 to be achieved. Similarly an appropriate choice of the amine in Step E will allow the different operable values of R^4 and R^5 to be achieved. Obvious variations and modifications of the method to produce similar and obvious variants thereof, will be apparent to one skilled in the art.

30

- 20 -


SCHEME 3

- The following examples are illustrative of the invention as contemplated by the inventors and should not be construed as being limits on the scope or spirit of the instant invention.
- 5

- 21 -

EXAMPLE 1

Preparation of 3-Benzylsulfonylamino-6-methyl-1-(methylene-carboxamidomethyl-2,5-dichlorophenyl)-2-pyridinone



5

Step A: 3-Benzylsulfonylamino-6-methyl-2-pyridinone

DPPA (35.6 ml, 165 mmol) was added to a stirred solution of 2-hydroxy-6-methylpyridine-3-carboxylic acid (22.97 g, 165 mmol) and triethylamine (23.0 ml, 165 mmol) in dry dioxane (300 ml) and the resulting solution was heated to reflux. After 16 h more triethylamine (23.0 ml, 165 mmol) and benzyl alcohol (17.1 ml, 165 mmol) were added and the solution was refluxed for a further 24 h. The reaction was concentrated *in vacuo* to remove most of the volatiles. The residue was partitioned between methylene chloride (500 ml) and brine (500 ml), acidified to pH 1 with 1 M HCl (165 ml). The aqueous layer was extracted methylene chloride (two times) and the combined organic layers were washed with sodium hydrogen carbonate solution and brine, dried (Na₂SO₄) and evaporated *in vacuo* to a brown solid. This was recrystallized from methanol, to give the title compound as a tan solid:

¹H NMR (300 MHz, CDCl₃) δ 2.29 (s, 3H, CH₃), 5.20 (s, 2H, PhCH₂), 6.06 (d, J=7.6 Hz, pyridinone-5-H), 7.32-7.43 (m, 5H, Ph), 7.67 (br s, 1H, CbzNH), 8.03 (br d, pyridinone-4-H).

20

Step B: 3-Benzylsulfonylamino-6-methyl-1-(t-butyl-methylenecarboxy)-2-pyridinone

25

Sodium hydride (5.3 g, 0.22 mol) was added to a stirred slurry of 3-benzylsulfonylamino-6-methyl-2-pyridinone (53.2 g, 0.20 mol) at 0°C. t-Butylbromoacetate (45 ml, 0.27 mol) was added to the resulting solution and a precipitate rapidly forms. The reaction was

- 22 -

warmed to rt over 1h and after 2h the solvent was evaporated *in vacuo* and the residue was partitioned between 1:1 water/brine (200 ml) and 6:1 THF/methylene chloride (700 ml). The organic layer was dried

- (Na₂SO₄) and evaporated *in vacuo* to a solid which was triturated with
5 hexane to give the title compound as a crystalline solid:
¹H NMR (400 Mz, CDCl₃) δ 1.47 (s, 9H), 2.25 (s, 3H), 4.75 (s, 2 H),
5.19 (s, 2H), 6.09 (d, J=7.8 Hz), 7.30-7.40 (m, 5H), 7.75 (br s, 1H), 7.94
(br d, 1H).

10 Step C: 3-Amino-6-methyl-1-(t-butyl-methylenecarboxy)-2-
pyridinone

- A mixture of 3-benzyloxycarbonylamino-6-methyl-1-(t-butyl-methylenecarboxy)-2-pyridinone (5.59 g, 15.0 mmol) and Pearlman's catalyst (0.56 g) in 4:1 ethanol/water (200 ml) was shaken in a
15 Parr apparatus under H₂ (50 psi) for 2 h. The reaction mixture was
filtered through celite and evaporated *in vacuo*, azeotroping with ethanol
to give the title compound as a solid:
¹H NMR (400 Mz, CDCl₃) δ 1.46 (s, 9H, t-Bu), 2.18 (s, 3H, Me), 4.02
(br s, 2H, NH₂), 4.74 (s, 2H, CH₂), 5.90 (d, J=7.3Hz, 1 H, pyridinone H-
20 5), 6.47 (d, J=7.3 Hz, 1H, pyridinone H-4).

Step D: 3-Benzylsulfonylamino-6-methyl-1-(t-butyl-
methylenecarboxy)-2-pyridinone

- Benzylsulfonyl chloride (3.15 g, 16.5 mmol) was added to a
25 stirred solution of 3-amino-6-methyl-1-(t-butyl-methylenecarboxy)-2-
pyridinone (3.55 g, 14.9 mmol) in pyridine (30 ml) at 0°C and as the
resulting solution was stirred a thick precipitate formed. After 1h the
reaction mixture was evaporated *in vacuo* to a paste which was
partitioned between methylene chloride and 10% potassium hydrogen
30 sulfate solution. The organic layer was dried (Na₂SO₄) and evaporated
in vacuo to give the title compound as a pale pink solid:
¹H NMR (400 Mz, CDCl₃) δ 1.51 (s, 9H, t-Bu), 2.26 (s, 3H, Me), 4.31
(s, 2H, PhCH₂), 4.75 (s, 2H, NCH₂), 6.01 (d, J=7.7Hz, 1H, pyridinone
H-5), 7.22-7.34 (m, 7H, remaining H).

- 23 -

Step E: 3-Benzylsulfonylamino-6-methyl-1-methylenecarboxy-2-pyridinone

- HCl gas was bubbled through a stirred suspension of 3-benzylsulfonylamino-6-methyl-1-(t-butyl-methylenecarboxy)-2-pyridinone (5.70 g, 14.52 mmol) in ethyl acetate (60 ml) at 0°C until a solution had formed which was saturated with HCl. After 1.5 h at RT a thick suspension had formed. The mixture was degassed with nitrogen and filtered to give the title compound as a solid:
- 5 ¹H NMR (400 Mz, CD₃OD) δ 2.32 (s, 3H, Me), 4.43 (s, 2H, PhCH₂), 4.89 (s, 2H, NCH₂), 6.14 (d, J=7.7Hz, 1H, pyridinone H-5), 7.28-7.33 (m, 6H, remaining H).
- 10


Step F: 3-Benzylsulfonylamino-6-methyl-1-(N-2,5-Dichloro benzyl-acetamido)-2-pyridinone

- EDC Hydrochloride (48 mg, 0.25 mmol) was added to a stirred mixture of 3-benzylsulfonylamino-6-methyl-1-methylenecarboxy-2-pyridinone (70 mg, 0.21 mmol), HOBt (34 mg, 0.25 mmol), 2,5-dichlorobenzylamine (44 mg, 0.25 mmol) and triethylamine (0.070 ml, 0.50 mmol) in DMF (2.5 ml) and the mixture was stirred for 16 h. The reaction was diluted with ethyl acetate and was washed with brine, dried (Na₂SO₄) and evaporated *in vacuo* to a solid. The crude product was purified by flash column chromatography on silica (50% ethylacetate/hexanes), to give the title compound as a crystalline solid:
- 15 ¹H NMR (400 Mz, CDCl₃) δ 2.43 (s, 3H, Me), 4.30 (s, 2H), 4.49 (d, J=6.1Hz, 2 H, CH₂N), 4.68 (s, 2H), 6.05 (d, J=7.7Hz, 1H), 7.16 (dt, =2.4 and 8.9 Hz, 1 H), 7.24-7.40 (m, 8H); MS (FAB) 494 (M+1)⁺.
- 20
- 25

- 24 -

EXAMPLE II

Preparation of 3-Benzylsulfonylamino-6-methyl-1-[Ethyl-(2-methylenecarboxamidomethyl-4-chlorophenoxy)-acetamido]-2-pyridinone

Step A: 4-Chlorosalicaldehyde Oxime

A solution of hydroxylamine hydrochloride (16.7 g, 0.24 mol) and sodium carbonate (12.7 g, 0.12 mol) in water (120 ml) was added to a stirred solution of 4-chlorosalicaldehyde (25.0 g, 0.16 mol) in ethanol (160 ml) and the resulting solution was heated to reflux. After 1 h the reaction was cooled, water (320 ml) was added and the resulting crystalline precipitate was isolated by filtration. A second crop was similarly collected and the combined solids were dried to give the title compound:

¹H NMR (400 Mz, CDCl₃) δ 6.92 (d, J=8.8Hz, 1 H), 7.15 (d, J=2.6Hz, 1H), 7.23 (dd, J=2.6 and 8.8 Hz, 1H), 7.26 (s, 1H), 8.16 (s, 1H), 9.71 (s, 1H).

Step B: 2-Hydroxy-5-Chlorobenzylamine

A mixture of 4-chlorosalicaldehyde oxime (10 g, 58.3 mmol) and 5% Rh/C (2.0 g) in ethanol (100 ml) containing concentrated sulfuric acid (10 ml) was shaken in a Parr apparatus under H₂ (60 psi) for 24 h. Water (100 ml) was added and the mixture was filtered through celite. The filtrate was concentrated until the product had crystallized out of solution. The solid was collected by filtration and the filtrate was further concentrated, adding water to give a second crop which was combined with the first to give after drying the title compound.

- 25 -

^1H NMR (400 Mz, CD_3OD) δ 4.07 (s, 2 H), 6.88 (d, $J=8.6\text{Hz}$, 1 H), 7.25 (dd, $J=2.6$ and 8.6Hz , 1H), 7.31 (d, $J=2.6\text{Hz}$, 1 H).

Step C: N-t-Butoxycarbonyl-2-Hydroxy-5-Chlorobenzylamine

5 A mixture of 2-hydroxy-5-chlorobenzylamine (1.22 g, 4.77 mmol assuming the bisulfate salt), $(\text{BOC})_2\text{O}$ (1.56 g, 7.16 mmol) and N-methylmorpholine (1.05 ml, 9.54 mmol) in DMF (10 ml) was stirred for 5 h at r.t. The reaction was partitioned between water and ethyl acetate and the organic layer was washed with 5% KHSO_4 solution (2 times),
10 sodium hydrogen carbonate solution and brine, dried (Na_2SO_4) and evaporated *in vacuo* to a solid. The crude product was recrystallized from ethyl acetate/hexanes (1:5, 12 ml) to give the title compound:
 ^1H NMR (400 Mz, CDCl_3) δ 1.44 (s, 9 H, t-Bu), 4.17 (d, $J=6.8\text{Hz}$, 2H, CH_2), 5.22 (br t, 1H, NH), 6.87 (d, $J=8.6\text{Hz}$, 1H, H-3), 7.03 (d, $J=$
15 2.6Hz, 1H, H-6), 7.15 (dd, $J=2.6$ and 8.6 Hz , 1H, H-4).

Step D: Ethyl-(2-t-Butoxycarbonylaminomethyl-4-Chlorophenoxy)-Acetate

A mixture of N-t-butoxycarbonyl-2-hydroxy-5-chloro-
20 benzylamine (730 mg, 2.83 mmol), Cs_2CO_3 (923 mg, 2.83 mmol) and ethylbromoacetate (0.314 ml, 2.83 mmol) on DMF (5 ml) was stirred for 2 h. The crude reaction mixture was partitioned between ethyl acetate and water and the organic layer was washed with brine, dried (Na_2SO_4) and evaporated *in vacuo* to an oil which was used for the next step.

25

Step E: 2-t-Butoxycarbonylaminomethyl-4-Chlorophenoxyacetic Acid

The product from Step D was suspended in 1:1:1
methanol/THF/ water (9 ml) and lithium hydroxide hydrate (126 mg, 3.0
30 mmol) was added. After 16 h the volatiles were removed *in vacuo* and the solution was diluted with water and was washed with ethyl acetate, adding sufficient brine to disperse the emulsion. The aqueous layer was acidified with 5% KHSO_4 solution and was extracted with methylene

- 26 -

chloride which was then dried (Na_2SO_4) and evaporated *in vacuo* to give the title compound as a solid:

^1H NMR (400 Mz, CDCl_3) δ 1.44 (s, 9H, t-Bu), 4.35 (br s, 2H, NCH_2), 4.62 (s, 2H, OCH_2), 5.04 (br s, 1H, NH), 6.74 (d, $J=7.9\text{Hz}$, 1H, H-3),
5 7.20 (d, $J=2.6\text{Hz}$, 1H, H-6), 7.24 (d obscured, 1H, H-4).

Step F: Ethyl-(2-t-Butoxycarbonylaminomethyl-4-Chlorophenoxy)-Acetamide

EDC Hydrochloride (249 mg, 1.3 mmol) was added to a
10 stirred mixture of 2-t-butoxycarbonylaminomethyl-4-chloro-
phenoxyacetic acid (316 mg, 1.0 mmol), HOBT (176 mg, 1.3 mmol),
ethylamine hydrochloride (106 mg, 1.3 mmol) and N-methylmorpholine
(0.396 ml, 3.6 mmol) in DMF (4 ml) and the mixture was stirred for 16 h.
The reaction was partitioned between ethylacetate and 5% KHSO_4
15 solution and the organic layer was washed with 5% KHSO_4 solution,
water, NaHCO_3 solution and brine, dried (Na_2SO_4) and evaporated *in vacuo* to a solid (333 mg) which was used for the next step.

Step G: Ethyl-(2-Aminomethyl-4-Chlorophenoxy)-Acetamide

20 Ethyl-(2-t-butoxycarbonylaminomethyl-4-chlorophenoxy)-
acetamide from Step F was dissolved in 2:1 methylene chloride/TFA (3
ml) and after 15 min the solvent was evaporated *in vacuo*. The residue
was dissolved in water and the solution was washed with methylene
chloride (twice). The aqueous layer was then basified with saturated
25 sodium carbonate solution and NaCl was added to saturation. The
mixture was extracted with ethyl acetate, and the organic layer was dried
(Na_2SO_4) and evaporated *in vacuo* to give the title compound as a
crystalline solid:

^1H NMR (300 MHz, CDCl_3) δ 1.12 (t, $J=7.3\text{ Hz}$, 3H, Me), 1.54 (s, 9H, t-
30 Bu), 3.31 (quintet, $J=7.3\text{ Hz}$, 2H, CH_2Me), 3.90 (s, 2H, NCH_2), 4.58 (s,
2H, OCH_2), 6.80 (d, $J=8.3\text{ Hz}$, 1H, H-3), 7.19-7.23 (m, 2H, H-4, H-6),
8.01 (br s, 1H, CONH).

- 27 -


Step H: 3-Benzylsulfonylamino-6-methyl-1-[Ethyl-(2-Methylenecarboxamidomethyl-4-Chlorophenoxy)-Acetamide]

DCC (103 mg, 0.50 mmol) was added to a stirred solution of ethyl-(2-aminomethyl-4-chlorophenoxy)-acetamide (137 mg, 0.57 mmol) and 3-benzylsulfonylamino-6-methyl-1-methylenecarboxy-2-pyridinone (168 mg, 0.0.50 mmol) in methylene chloride (3 ml). After 3 h the resulting thick mixture was filtered through celite, washing the pad with a large volume of methylene chloride since the product is sparingly soluble, and the filtrate was evaporated *in vacuo* to a solid. The crude product was purified by flash column chromatography on silica (eluting with 3:1 hexanes/acetone followed by a methanol/chloroform gradient, 2-4% methanol) to give the title compound as a crystalline solid, m.p. 210-213°C:

¹H NMR (400 Mz, DMSO) δ 0.98 (t, J=7.2Hz, 3H, Me), 2.25 (s, 3H, Me), 3.11 (quintet, J=7.2Hz, 2H, CH₂Me), 4.40 (d, J=5.5Hz, 2H, CH₂NH), 4.49 (s, 2H), 4.50 (s, 2H), 4.79 (s, 2H), 6.09 (d, J=7.7Hz, 1H), 6.94 (d, J=8.6Hz, 1 H), 7.12 (d, J=7.5Hz, 1H), 7.26-7.33 (m, 7H), 8.02 (br t, 1H), 8.57 (s, 1 H), 8.75 (br s, 1H); MS (FAB) 561 (M+1)⁺.

Using the procedure of Example 2, the following compounds were prepared:

- 28 -

EXAMPLE 33-Benzylsulfonylamino-6-methyl-1-[cyclopropyl-(2-Methylene-carboxamidomethyl-4-Chlorophenoxy)-Acetamido]-2-Pyridinone

5


DCC (103 mg, 0.50 mmol) was added to a stirred solution of cyclopropyl-(2-aminomethyl-4-chlorophenoxy)-acetamide (127 mg, 0.50 mmol,) and 3-benzylsulfonylamino-6-methyl-1-methylenecarboxy-2-pyridinone (168 mg, 0.50 mmol) in methylene chloride (2 ml). After 16 h the resulting thick mixture was filtered through celite, washing through with 1:1 methanol/chloroform and the filtrate was evaporated *in vacuo* to a solid. The crude product was purified by flash column chromatography on silica (eluting with 3:1 hexanes/acetone followed by a methanol/chloroform gradient, 2-4% methanol) to give the title compound as a crystalline solid, m.p. > 200°C:

15

¹H NMR (400 Mz, CD₃OD) δ 0.50-0.65 (m, 4H, CH₂CH₂), 2.29 (s, 3H, Me), 2.72 (m, 1H, CH), 4.41 (s, 2H), 4.48 (s, 2H), 4.49 (s, 2H), 4.81 (s, 2H), 6.15 (d, J=7.7Hz, 1H), 6.90 (d, J=8.8Hz, 1H), 7.24-7.35 (m, 8H); MS (FAB) 573 (M+1)⁺.

20

- 29 -

EXAMPLE 43-Benzylsulfonylamino-6-methyl-1-(2-Methylenecarboxamidomethyl-4-Chlorophenoxyacetamido)-2-Pyridinone

5


DCC (63 mg, 0.307 mmol) was added to a stirred solution of 2-aminomethyl-4-chlorophenoxyacetamide (101 mg, 0.307 mmol,) and 3-benzylsulfonylamino-6-methyl-1-methylenecarboxy-2-pyridinone (103 mg, 0.307 mmol) in methylene chloride (2 ml). After 66 h the resulting thick mixture was filtered through celite, washing through with 1:1 methanol/methylene chloride and the filtrate was evaporated *in vacuo* to a solid. The crude product was purified by flash column chromatography on silica (eluting with 3:1 hexanes/acetone followed by a methanol/chloroform gradient, 2-5% methanol) to give the title compound as a crystalline solid, m.p. > 200°C:

¹H NMR (300 MHz, DMSO) δ 2.48 (s, 3 H, Me), 4.36 (d, J = 5.9 Hz, 2 H, CH₂NH), 4.46 (s, 2H), 4.50 (s, 2H), 4.77 (s, 2H), 6.08 (d, J=7.6Hz, 1H), 6.91 (d, J=8.6Hz, 1H), 7.12 (d, J=7.6Hz, 1H), 7.24-7.33 (m, 7H), 7.45 (br s, 2H, NH₂), 8.57 (s, 1H, SO₂NH), 8.71 (br t, 1H, CONH); MS (FAB) 533 (M+1)⁺.

10
15
20

In addition, the following examples were prepared:

- 30 -

EXAMPLE 53-Benzylsulfonylamino-6-methyl-1-(2-Methylenecarboxamidomethyl-4-Chlorophenoxy)-2-Pyridinone

5


EDC Hydrochloride (236 mg, 1.23 mmol) was added to a stirred mixture of 3-benzylsulfonylamino-6-methyl-1-methylenecarboxy-2-pyridinone (415 mg, 1.23 mmol), HOBt (167 mg, 1.23 mmol), 2-hydroxy-5-chlorobenzylamine (195 mg, the product of Step B, Example B) and NMM (0.136 ml, 1.23 mmol) in DMF (1.2 ml) and the mixture was stirred for 3 h. The reaction was diluted with ethyl acetate and was washed with water, dried (Na₂SO₄) and evaporated *in vacuo* to a solid. The crude product was purified by flash column chromatography on silica (ethylacetate/hexanes/2% acetic acid gradient, 50-80% ethyl acetate), to give the title compound as a crystalline solid, m.p. > 200°C: ¹H NMR (400 Mz, CDCl₃) δ 2.42 (s, 3H, Me), 4.22 (s, 2H), 4.26 (d, J=6.4Hz, 2 H, CH₂NH), 4.44 (s, 2H), 6.08 (d, J=7.7Hz, 1H), 6.72 (d, J=8.6Hz, 1H), 7.01-7.15 (m, 7H), 7.43 (d, J=7.7Hz, 1H), 8.01 (br t, 1H, CONH); MS (FAB) 476 (M+1)⁺.

20

- 31 -

EXAMPLE 6

3-Benzylsulfonylamino-6-methyl-1-[2,2,2-Trifluoroethyl-(2-Methylenecarboxamidomethyl-4-Chloro)-phenoxy]-2-Pyridinone



5


DCC (25 mg, 0.12 mmol) was added to a stirred solution of 2-(2,2,2-trifluoroethyl)-5-chlorobenzylamine (29 mg, 0.12 mmol,) and 3-benzylsulfonylamino-6-methyl-1-methylenecarboxy-2-pyridinone (61 mg, 0.18 mmol) in methylene chloride (0.7 ml). After 16 h the resulting thick mixture was filtered through celite, washing with methylene chloride and the filtrate was evaporated *in vacuo* to a solid. The crude product was purified by flash column chromatography on silica (eluting with 3:1 hexanes/acetone followed by 50% ethyl acetate/hexanes) to give a crystalline solid which was triturated with methylene chloride to give the title compound as a crystalline solid, m.p. > 200°C:

15

¹H NMR (300 MHz, DMSO) δ 2.26 (s, 3H, Me), 4.28 (d, J=5.6Hz, 2H, CH₂NH), 4.51 (s, 2H), 4.75-4.83 (m, 4 H), 6.09 (d, J=7.6Hz, 1H), 7.01-7.31 (m, 9 H), 8.56 (br s, 1H, SO₂NH), 8.70 (br t, 1H, CONH); MS (FAB) 598 (M+1)⁺.

20

- 32 -

EXAMPLE 73-Benzylsulfonylamino-6-methyl-1-(Methylenecarboxamidomethyl-3-Chlorophenyl)-2-Pyridinone

5
DCC (43 mg, 0.21 mmol) was added to a stirred solution of 3-chlorobenzylamine (0.025 ml, 0.21 mmol,) and 3-benzylsulfonylamino-6-methyl-1-methylenecarboxy-2-pyridinone (70 mg, 0.21 mmol) in methylene chloride (1.0 ml). After 16 h the resulting thick mixture was
10 filtered through celite, washing with methylene chloride and the filtrate was evaporated *in vacuo* to a solid. The crude product was purified by flash column chromatography on silica (eluting with 3:1 hexanes/acetone followed by an ethyl acetate/hexanes gradient, 60-100% ethyl acetate) to give a crystalline solid which was triturated with methanol to give the
15 title compound as a solid, m.p. 176-178°C:
¹H NMR (400 Mz, CDCl₃, 1 drop CD₃OD) δ 2.41 (s, 3H, Me), 4.31 (s, 2H), 4.41 (s, 2H), 4.67 (s, 2H), 6.08 (d, J=7.6 Hz, 1H), 7.15-7.34 (m, 10H); MS (FAB) 460 (M+1)⁺.

20

EXAMPLE 8IN VITRO ASSAY FOR DETERMINING PROTEINASE INHIBITION

Assays of human α-thrombin and human trypsin were performed by the methods substantially as described in Thrombosis Research, Issue No. 70, page 173 (1993) by S.D. Lewis *et al.*
25

The assays were carried out at 25°C in 0.05 M TRIS buffer pH 7.4, 0.15 M NaCl, 0.1% PEG. Trypsin assays also contained 1 mM CaCl₂. In assays wherein rates of hydrolysis of a *p*-nitroanilide (pna) substrate were determined, a Thermomax 96-well plate reader was used

- 33 -

was used to measure (at 405 nm) the time dependent appearance of *p*-nitroaniline. sar-PR-pna was used to assay human α -thrombin ($K_m=125 \mu M$) and bovine trypsin ($K_m=125 \mu M$). *p*-Nitroanilide substrate concentration was determined from measurements of absorbance at 342 nm using an extinction coefficient of $8270 \text{ cm}^{-1} \text{ M}^{-1}$.

In certain studies with potent inhibitors ($K_i < 10 \text{ nM}$) where the degree of inhibition of thrombin was high, a more sensitive activity assay was employed. In this assay the rate of thrombin catalyzed hydrolysis of the fluorogenic substrate Z-GPR-afc ($K_m=27 \mu M$) was determined from the increase in fluorescence at 500 nm (excitation at 400 nm) associated with production of 7-amino-4-trifluoromethyl coumarin. Concentrations of stock solutions of Z-GPR-afc were determined from measurements of absorbance at 380 nm of the 7-amino-4-trifluoromethyl coumarin produced upon complete hydrolysis of an aliquot of the stock solution by thrombin.

Activity assays were performed by diluting a stock solution of substrate at least tenfold to a final concentration $\leq 0.1 K_m$ into a solution containing enzyme or enzyme equilibrated with inhibitor. Times required to achieve equilibration between enzyme and inhibitor were determined in control experiments. Initial velocities of product formation in the absence (V_o) or presence of inhibitor (V_i) were measured. Assuming competitive inhibition, and that unity is negligible compared $K_m/[S]$, $[I]/e$, and $[I]/e$ (where $[S]$, $[I]$, and e respectively represent the total concentrations, of substrate, inhibitor and enzyme), the equilibrium constant (K_i) for dissociation of the inhibitor from the enzyme can be obtained from the dependence of V_o/V_i on $[I]$ shown in equation 1.


$$V_o/V_i = 1 + [I]/K_i \quad (1)$$

The activities shown by this assay indicate that the compounds of the invention are therapeutically useful for treating various conditions in patients suffering from unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated

- 34 -

intravascular coagulation, and reocclusion or restenosis of recanalized vessels. The inhibitory activity of each of the following compounds against human thrombin, represented by K_i , is less than 15 nM. These are selective compounds, as evidenced by their inhibitory activity against

5 human trypsin (represented by K_i), which is at least 1800 nM.

TABLE I

 R

H

Cl

OH

 $\text{OCH}_2\text{CONHEt}$ $\text{OCH}_2\text{CONHC}_3\text{H}_5$ $\text{OCH}_2\text{CONH}_2$ OCH_2CF_3

- 35 -

EXAMPLE 9In Vivo Studies To Measure Thrombotic Occlusions

Applicants have conducted *in vivo* studies of the compounds claimed herein using the following rat ferric chloride assay substantially as described in *Thrombosis Research*, No. 60, page 269(1990) by Kurtz et al.

In the assay used to determine *in vivo* activity of the thrombin inhibitors or the invention, Male Sprague-Dawley rats (body weights 200-350 grams) were anesthetized with dial-urethane solution (0.1 ml/100 gm body weight i.p.), and a lateral tail vein was cannulated with a 23 gauge needle connected to a 12 inch length of PE50 tubing. The tubing was attached to a 3-way valve by a tubing adapter. Saline (control) or test compound, as appropriate, was administered via the tail vein catheter. A tracheostomy was performed with a 0.75 inch length of PE205 tubing. The right carotid artery was exposed and a 1.3 mm diameter Doppler flow probe was placed on the vessel. Body temperature was maintained at 37°C using a heat lamp.

Rats (8-10/group) were randomized to continuous intravenous infusions of saline or test compound administered via the tail vein at a rate of 0.028 ml/min. Treatment infusions were initiated 60 min before the placement of a 3 mm square piece of Whatman No. 1 filter paper saturated with 35% FeCl₃ onto the exposed carotid artery distal to the flow probe. Treatment infusions were continued for an additional 90 minutes after the application of FeCl₃ (total infusion duration 150 minutes) if thrombotic occlusions did not occur, or were terminated 30 minutes after thrombotic occlusion of the vessel. Time to occlusion was defined as the time from application of FeCl₃ to thrombotic occlusion of the vessel. At the termination of the study (90 minutes after application of FeCl₃ in animals which did not occlude, or at 30 minutes after thrombotic occlusion), 3 ml blood samples were drawn by cardiac puncture into 0.3 ml of 3.8% sodium citrate.

The results show that the compounds of the invention are effective in preventing thrombotic occlusions.

- 36 -

EXAMPLE 10Tablet Preparation

Tablets containing 25.0, 50.0, and 100.0 mg., respectively,
 5 of the following active compounds are prepared as illustrated below:

3-Benzylsulfonylamino-6-methyl-1-(methylenecarboxamidomethyl-2,5-
 dichlorophenyl)-2-pyridinone,

10 3-Benzylsulfonylamino-6-methyl-1-[Ethyl-(2-methylene-
 carboxamidomethyl-4-chlorophenoxy)-acetamido]-2-pyridinone,

3-Benzylsulfonylamino-6-methyl-1-[cyclopropyl-(2-Methylene-
 carboxamidomethyl-4-Chlorophenoxy)-Acetamido]-2-Pyridinone,

15 3-Benzylsulfonylamino-6-methyl-1-(2-Methylenecarboxamidomethyl-4-
 Chlorophenoxyacetamido)-2-Pyridinone

20 TABLE FOR DOSES CONTAINING FROM
25-100MG OF THE ACTIVE COMPOUND

		Amount-mg		
25	Active Compound	25.0	50.0	100.0
	Microcrystalline cellulose	37.25	100.0	200.0
	Modified food corn starch	37.25	4.25	8.5
	Magnesium stearate	0.50	0.75	1.5

All of the active compound, cellulose, and a portion of the
 corn starch are mixed and granulated to 10% corn starch paste. The
 resulting granulation is sieved, dried and blended with the remainder of


- 37 -

the corn starch and the magnesium stearate. The resulting granulation is then compressed into tablets containing 25.0, 50.0, and 100.0 mg, respectively, of active ingredient per tablet.

- 38 -

WHAT IS CLAIMED IS:

1. A compound having the formula:



5 wherein
W is

hydrogen,
R¹-,
10 R¹OC(O)-,
R¹C(O)-,
R¹SO₂-,
R¹NHSO₂-,
(R¹)₂NSO₂-,
15 R¹(CH₂)_nNHC(O)-,
(R¹)₂CH(CH₂)_nNHC(O)-, or
wherein n is 0-4;

R¹ is
20 R²(CH₂)_r-, where r is 0-4,
(R²)(OR²)CH(CH₂)_p-, where p is 1-4,
(R²)₂CH(CH₂)_r-, where r is 0-4 and each R² can be the same or
different, and wherein (R²)₂ can also form a ring with CH
represented by C₃₋₇ cycloalkyl, C₇₋₁₂ bicyclic alkyl, C₁₀₋₁₆
25 tricyclic alkyl, or a 5- to 7- membered mono- or bicyclic
heterocyclic ring which can be saturated or unsaturated, and
which contains from one to three heteroatoms selected from the
group consisting of N, O and S,
R²O(CH₂)_p-, wherein p is 1-4, or

- 39 -

$R^2(COOR^3)(CH_2)_r-$, where r is 1-4;

R^2 and R^{14} are independently selected from

- 5 -phenyl, unsubstituted or substituted with one or more of
 C₁₋₄ alkyl, C₁₋₄ alkoxy, halogen, hydroxy, COOH, or CONH₂,
 naphthyl,
 biphenyl,
 a 5- to 7- membered mono- or a 9- to 10-membered bicyclic
10 heterocyclic ring which can be saturated or unsaturated, and
 which contains from one to four heteroatoms selected from the
 group consisting of N, O and S,
 C₁₋₄ alkyl,
 C₃₋₇ cycloalkyl,
 C₇₋₁₂ bicyclic alkyl, or
15 C₁₀₋₁₆ tricyclic alkyl;

R^3 and $R^{3'}$ are independently

- C₁₋₄ alkyl,
 C₃₋₇ cycloalkyl, or
20 trifluoromethyl;

R^4 is

- hydrogen,
 C₁₋₄ alkyl,
25 C₁₋₄ alkoxy,
 halogen,
 -OCH₂CF₃,
 -COOH,
 -OH,
30 -COOR⁶, where R⁶ is C₁₋₄alkyl,
 -CONR⁷R⁸, where R⁷ and R⁸ are independently
 hydrogen or C₁₋₄alkyl,
 -(CH₂)₁₋₄OH,
 -CH₂NHC(O)CH₃,

- 40 -

- CH₂NHC(O)CF₃,
-CH₂NHSO₂CH₃,
-SO₂NH₂,
-(CH₂)₁₋₄SO₂NR⁷R⁸,
5 -(CH₂)₁₋₄SO₂R⁶,
a 5- to 7- membered mono- or a 9- to 10-membered bicyclic
heterocyclic ring which can be saturated or unsaturated, and
which contains from one to four heteroatoms selected from the
group consisting of N, O and S,
10 -XCH₂CO₂H,
-XCH₂CO₂CH₃,
-XCH₂CO₂(CH₂)₁₋₃CH₃,
-X(CHR⁹)₁₋₃C(O)NR¹⁰R¹¹,
wherein
15 R⁹ is H or C₁₋₄ alkyl,
R¹⁰ and R¹¹ are independently
hydrogen,
C₃₋₇ cycloalkyl,
aryl,
20 heteroaryl,
heterocycloalkyl,
C₁₋₄ alkyl unsubstituted or substituted with one or more of
hydroxy,
COOH,
25 amino,
dialkylamino,
aryl,
heteroaryl, or
heterocycloalkyl, or
30 R¹⁰ and R¹¹ are joined to form a four to seven
membered cycloalkyl ring unsubstituted or
substituted with hydroxy, amino or aryl, or
-XCH₂R¹⁴,

- 41 -

wherein X is O, S or CH₂;

R⁵ is

- 5 hydrogen,
 halogen,
 C₁₋₄ alkyl,
 C₁₋₄ alkoxy,
 CN, or
 CO₂NH₂,
10 and pharmaceutically acceptable salts thereof.

2. A compound of Claim 1, and pharmaceutically acceptable salts thereof, wherein W is R¹ or R¹SO₂.

- 15 3. A compound of Claim 2, and pharmaceutically acceptable salts thereof, wherein R¹ is R²(CH₂)_r, or (R²)₂CH(CH₂)_r, phenyl-CH₂SO₂, or diphenyl-CHSO₂.

- 20 4. A compound of Claim 3, and pharmaceutically acceptable salts thereof, wherein R¹ is phenyl-CH₂SO₂, or diphenyl-CHSO₂.

- 25 5. A compound of Claim 4, and pharmaceutically acceptable salts thereof, wherein R³ is C₁₋₄ alkyl.

6. A compound of Claim 5, and pharmaceutically acceptable salts thereof, wherein R³ is methyl and R^{3'} is hydrogen.

- 30 7. A compound of claim 6, and pharmaceutically acceptable salts thereof, wherein

R⁴ is




hydrogen,
chlorine,

- 42 -

- 5 OH,
 OCH₂CF₃
 OCH₂C(O)NH₂
 OCH₂C(O)NHCH₂CH₃, or
 OCH₂C(O)NH(CHCH₂CH₂); and





R⁵ is chlorine.

- 10 8. The compound of Claim 7, and pharmaceutically
 acceptable salts thereof, selected from:



15

- 43 -




- 5
9. A composition for inhibiting thrombin in blood
- 10 comprising a compound of Claim 1 and a pharmaceutically acceptable carrier.

- 44 -

10. A composition for inhibiting formation of blood platelet aggregates in blood comprising a compound of Claim 1 and a pharmaceutically acceptable carrier.
- 5 11. A composition for inhibiting thrombus formation in blood comprising a compound of Claim 1 and a pharmaceutically acceptable carrier.
- 10 12. A method for inhibiting thrombin in blood comprising adding to the blood a composition of Claim 7.
- 15 13. A method for inhibiting formation of blood platelet aggregates in blood comprising adding to the blood a composition of Claim 7.
14. A method for inhibiting thrombus formation in blood comprising adding to the blood a composition of Claim 7.
- 20 15. A method for inhibiting thrombus formation in blood comprising adding to the blood a compound of Claim 1 with a fibrinogen receptor antagonist.
- 25 16. The use of a compound of Claim 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for inhibiting thrombus formation, preventing thrombus formation, inhibiting thrombin, inhibiting formation of fibrin, and inhibiting formation of blood platelet aggregates, in a mammal.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/02408

A. CLASSIFICATION OF SUBJECT MATTER IPC(6) :A61K 31/44; C07D 213/72 US CL :514/349; 546/297 According to International Patent Classification (IPC) or to both national classification and IPC				
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 514/349; 546/297 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAS ONLINE				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
A	BROWN et al. Design of Orally Active, Non-Peptidic Inhibitors of Human Leukocyte Elastase. J. Med. Chem. 1994, Vol. 37, No. 9, pages 1259-1261, especially page 1260, Table 1.	1-16		
A	EDWARDS et al. Design, Synthesis, and Kinetic Evaluation of a Unique Class of Elastase Inhibitors, the Peptidyl α -Ketobenzoxazoles and the X-ray Crystal Structure of the Covalent Complex between Porcine Pancreatic Elastase and Ac-Ala-Pro-Val-2-Benzoxazole. J. Am. Chem. Soc. 1992, Vol. 114, No. 5, pages 1854-1863, especially page 1855.	1-16		
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.				
<table border="0"> <tr> <td> * Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed </td> <td> "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "A" document member of the same patent family </td> </tr> </table>			* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "A" document member of the same patent family
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "A" document member of the same patent family			
Date of the actual completion of the international search 22 MAY 1997		Date of mailing of the international search report 06 JUN 1997		
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer EVELYN HUANG  Telephone No. (703) 308-1235		